vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and Farmmi, Inc. (FAMI). Click either name above to swap in a different company.

Farmmi, Inc. is the larger business by last-quarter revenue ($16.1M vs $13.0M, roughly 1.2× Aquestive Therapeutics, Inc.). Farmmi, Inc. runs the higher net margin — -0.3% vs -244.8%, a 244.5% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs -55.7%). Farmmi, Inc. produced more free cash flow last quarter ($14.6M vs $-8.6M).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

Farmmi Inc. is a company that processes and sells agricultural products in China and abroad; it grows and markets shiitake and wood ear mushrooms and other edible fungi products, including bamboo fungi, chestnut mushroom, trumpet royale, hen of the woods, lawyer's wig, and lion's mane mushroom. It also operates Farmmi Jicai, an online store that sells edible fungi products under the Forasen and Farmmi Liangpin brands. In addition, the company exports dried whole and sliced shiitake mushrooms,...

AQST vs FAMI — Head-to-Head

Bigger by revenue
FAMI
FAMI
1.2× larger
FAMI
$16.1M
$13.0M
AQST
Growing faster (revenue YoY)
AQST
AQST
+65.4% gap
AQST
9.7%
-55.7%
FAMI
Higher net margin
FAMI
FAMI
244.5% more per $
FAMI
-0.3%
-244.8%
AQST
More free cash flow
FAMI
FAMI
$23.1M more FCF
FAMI
$14.6M
$-8.6M
AQST

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
AQST
AQST
FAMI
FAMI
Revenue
$13.0M
$16.1M
Net Profit
$-31.9M
$-44.0K
Gross Margin
55.2%
5.0%
Operating Margin
-221.6%
-4.1%
Net Margin
-244.8%
-0.3%
Revenue YoY
9.7%
-55.7%
Net Profit YoY
-86.8%
-107.0%
EPS (diluted)
$-0.26
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
FAMI
FAMI
Q4 25
$13.0M
Q3 25
$12.8M
Q2 25
$10.0M
Q1 25
$8.7M
$16.1M
Q4 24
$11.9M
Q3 24
$13.5M
Q2 24
$20.1M
Q1 24
$12.1M
$36.4M
Net Profit
AQST
AQST
FAMI
FAMI
Q4 25
$-31.9M
Q3 25
$-15.4M
Q2 25
$-13.5M
Q1 25
$-22.9M
$-44.0K
Q4 24
$-17.1M
Q3 24
$-11.5M
Q2 24
$-2.7M
Q1 24
$-12.8M
$630.5K
Gross Margin
AQST
AQST
FAMI
FAMI
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
5.0%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Q1 24
63.6%
5.9%
Operating Margin
AQST
AQST
FAMI
FAMI
Q4 25
-221.6%
Q3 25
-89.6%
Q2 25
-113.6%
Q1 25
-222.1%
-4.1%
Q4 24
-114.4%
Q3 24
-61.2%
Q2 24
0.3%
Q1 24
-74.3%
2.5%
Net Margin
AQST
AQST
FAMI
FAMI
Q4 25
-244.8%
Q3 25
-120.6%
Q2 25
-135.4%
Q1 25
-263.0%
-0.3%
Q4 24
-143.7%
Q3 24
-85.0%
Q2 24
-13.7%
Q1 24
-106.4%
1.7%
EPS (diluted)
AQST
AQST
FAMI
FAMI
Q4 25
$-0.26
Q3 25
$-0.14
Q2 25
$-0.14
Q1 25
$-0.24
$-0.04
Q4 24
$-0.18
Q3 24
$-0.13
Q2 24
$-0.03
Q1 24
$-0.17
$1.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
FAMI
FAMI
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$166.4M
Total Assets
$160.4M
$230.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
FAMI
FAMI
Q4 25
Q3 25
$129.1M
Q2 25
$60.5M
Q1 25
$68.7M
Q4 24
$71.5M
Q3 24
$77.9M
Q2 24
$89.9M
Q1 24
$95.2M
Total Debt
AQST
AQST
FAMI
FAMI
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
Q1 24
$45.0M
Stockholders' Equity
AQST
AQST
FAMI
FAMI
Q4 25
$-33.7M
Q3 25
$-4.1M
Q2 25
$-72.6M
Q1 25
$-60.9M
$166.4M
Q4 24
$-60.2M
Q3 24
$-45.4M
Q2 24
$-35.5M
Q1 24
$-36.3M
$164.4M
Total Assets
AQST
AQST
FAMI
FAMI
Q4 25
$160.4M
Q3 25
$163.6M
Q2 25
$93.7M
Q1 25
$102.2M
$230.4M
Q4 24
$101.4M
Q3 24
$110.0M
Q2 24
$117.6M
Q1 24
$129.5M
$171.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
FAMI
FAMI
Operating Cash FlowLast quarter
$-8.5M
$14.6M
Free Cash FlowOCF − Capex
$-8.6M
$14.6M
FCF MarginFCF / Revenue
-65.7%
90.1%
Capex IntensityCapex / Revenue
0.7%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-53.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
FAMI
FAMI
Q4 25
$-8.5M
Q3 25
$-12.6M
Q2 25
$-7.9M
Q1 25
$-23.4M
$14.6M
Q4 24
$-6.5M
Q3 24
$-11.9M
Q2 24
$-7.0M
Q1 24
$-10.4M
$-14.9M
Free Cash Flow
AQST
AQST
FAMI
FAMI
Q4 25
$-8.6M
Q3 25
$-12.9M
Q2 25
$-8.0M
Q1 25
$-23.5M
$14.6M
Q4 24
$-6.5M
Q3 24
$-12.0M
Q2 24
$-7.0M
Q1 24
$-10.4M
FCF Margin
AQST
AQST
FAMI
FAMI
Q4 25
-65.7%
Q3 25
-100.6%
Q2 25
-80.2%
Q1 25
-269.9%
90.1%
Q4 24
-54.8%
Q3 24
-88.3%
Q2 24
-35.0%
Q1 24
-86.4%
Capex Intensity
AQST
AQST
FAMI
FAMI
Q4 25
0.7%
Q3 25
1.8%
Q2 25
1.1%
Q1 25
1.5%
0.1%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
0.2%
0.0%
Cash Conversion
AQST
AQST
FAMI
FAMI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-23.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons